1 Overall survival |
11 |
2221 |
Peto Odds Ratio (95% CI) |
0.97 [0.87, 1.09] |
2 Freedom from treatment failure |
6 |
718 |
Peto Odds Ratio (95% CI) |
1.11 [0.91, 1.35] |
3 Neutropenia |
8 |
1013 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.67 [0.60, 0.73] |
4 Febrile Neutropenia, ANC < 1000 |
5 |
360 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.74 [0.62, 0.89] |
5 Febrile Neutropenia, ANC < 500 |
3 |
604 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.59 [0.48, 0.72] |
6 Infection |
11 |
1292 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.74 [0.64, 0.85] |
7 Parenteral antibiotic treatment |
4 |
359 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.82 [0.57, 1.18] |
8 Overall mortality during chemotherapy |
11 |
1170 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.93 [0.60, 1.43] |
9 Infection related mortality during chemotherapy |
12 |
1835 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.93 [0.51, 1.71] |
10 Complete response |
13 |
2368 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.03 [0.95, 1.10] |
11 Adverse events: bone pain |
9 |
1204 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.57 [2.09, 6.12] |
12 Adverse events: thrombosis and related complications (TIA, MI, cerebral non‐hemorhagic infarction) |
5 |
425 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.29 [0.56, 3.01] |
13 Adverse events: skin rash |
2 |
232 |
Risk Ratio (M‐H, Fixed, 95% CI) |
7.69 [2.84, 20.82] |
14 Adverse events: injection site reaction |
2 |
337 |
Risk Ratio (M‐H, Fixed, 95% CI) |
6.55 [3.01, 14.25] |
15 Adverse events: myalgia |
2 |
232 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.94 [0.60, 1.45] |
16 Adverse events: mucositis |
4 |
696 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.95 [0.64, 1.41] |
17 Adverse events: headache |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
18 Withdrawals due to adverse events |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
18.1 GM‐CSF |
2 |
228 |
Risk Ratio (M‐H, Fixed, 95% CI) |
4.97 [2.07, 11.96] |